IRIS
CARLOMAGNO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.199
NA - Nord America 4.055
EU - Europa 3.103
SA - Sud America 530
Continente sconosciuto - Info sul continente non disponibili 173
AF - Africa 95
OC - Oceania 5
Totale 12.160
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.862
SG - Singapore 1.851
RU - Federazione Russa 1.220
IT - Italia 859
VN - Vietnam 823
CN - Cina 707
BR - Brasile 419
HK - Hong Kong 322
DE - Germania 206
FR - Francia 162
UA - Ucraina 145
FI - Finlandia 143
BD - Bangladesh 138
CA - Canada 125
IE - Irlanda 95
GB - Regno Unito 92
IN - India 90
JP - Giappone 60
NL - Olanda 58
AR - Argentina 41
IQ - Iraq 35
SE - Svezia 31
MX - Messico 30
PH - Filippine 30
ZA - Sudafrica 26
PL - Polonia 24
CI - Costa d'Avorio 22
ES - Italia 18
KR - Corea 18
TH - Thailandia 17
CO - Colombia 16
EC - Ecuador 16
TR - Turchia 13
ID - Indonesia 12
PK - Pakistan 12
VE - Venezuela 12
AT - Austria 11
JM - Giamaica 11
LT - Lituania 10
TW - Taiwan 9
AZ - Azerbaigian 8
MA - Marocco 8
CL - Cile 7
KE - Kenya 7
MY - Malesia 7
PY - Paraguay 7
GE - Georgia 6
NP - Nepal 6
UZ - Uzbekistan 6
AU - Australia 5
CR - Costa Rica 5
HN - Honduras 5
OM - Oman 5
TN - Tunisia 5
UY - Uruguay 5
AL - Albania 4
BO - Bolivia 4
CH - Svizzera 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
GT - Guatemala 3
HR - Croazia 3
IL - Israele 3
LY - Libia 3
PA - Panama 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
EU - Europa 2
GR - Grecia 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NG - Nigeria 2
PE - Perù 2
QA - Qatar 2
RO - Romania 2
SA - Arabia Saudita 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
CV - Capo Verde 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
GN - Guinea 1
GP - Guadalupe 1
GY - Guiana 1
Totale 11.973
Salva come PNG Salva come JPEG
Città #
Singapore 779
San Jose 690
Moscow 313
Hong Kong 304
Ashburn 273
Naples 258
Ho Chi Minh City 242
Chandler 237
Beijing 209
Hanoi 196
Jacksonville 148
Santa Clara 145
The Dalles 118
Lauterbourg 107
Los Angeles 102
Millbury 100
Princeton 98
Council Bluffs 82
Napoli 79
Buffalo 69
Munich 68
Nanjing 66
New York 57
Phoenix 57
Boston 54
Ottawa 53
Wilmington 51
Tokyo 48
Hefei 47
São Paulo 46
Amsterdam 45
Dallas 42
Haiphong 34
Chicago 32
Da Nang 32
Redondo Beach 31
Montreal 30
Nanchang 29
Woodbridge 26
Orem 25
Helsinki 23
Brooklyn 22
Turku 22
Rome 21
Warsaw 21
Salerno 20
Atlanta 19
Augusta 19
Chennai 19
Des Moines 19
Milan 19
Mexico City 18
Shenyang 18
Seattle 17
Frankfurt am Main 16
Shanghai 16
Hebei 15
Houston 15
Hải Dương 15
Lawrence 15
Nocera Superiore 15
Poplar 15
London 14
Rio de Janeiro 14
Baghdad 13
Falls Church 13
Nuremberg 13
Boardman 12
Giugliano in Campania 12
Kronberg 12
Kunming 12
Ann Arbor 11
Changsha 11
Manchester 11
Ninh Bình 11
Thái Bình 11
Denver 10
Hangzhou 10
Tianjin 10
Toronto 10
Waldbuttelbrunn 10
Biên Hòa 9
Can Tho 9
Kochi 9
Mumbai 9
Nola 9
San Francisco 9
San Mateo 9
Washington 9
Brasília 8
Dhaka 8
Düsseldorf 8
Erbil 8
Guarulhos 8
Johannesburg 8
Nha Trang 8
Palermo 8
Seoul 8
Stockholm 8
Thái Nguyên 8
Totale 6.201
Salva come PNG Salva come JPEG
Nome #
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms 253
Mechanisms of RET mediated signal transduction 207
NCOA4 links iron bioavailability to DNA metabolism 190
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms 184
Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis 180
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase 171
NCOA4 inhibits initiation of DNA replication to maintain genome stability 168
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 162
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 155
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 153
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 152
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STING 149
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 149
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases 147
Molecular biology of the MEN2 gene 144
NCOA4 Deficiency Impairs Systemic Iron Homeostasis 143
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 142
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology 140
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati 138
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 136
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 136
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 134
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 133
Different mutations of the RET gene cause different human tumoral diseases. 132
NCOA4 Links Iron Bioavailability to DNA Metabolism 130
BAY 43-9006 inhibition of oncogenic RET mutants 129
Molecular mechanisms of RET activation in human cancer 129
Ret gene fusions in malignancies of the thyroid and other tissues 129
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 128
Ret-mediated mitogenesis requires Src kinase activity. 125
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 122
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. 122
The extent of linkage disequilibrium in four populations with distinct demographic histories 117
The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia 117
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 115
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 114
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 114
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 114
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model 113
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer 112
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose 112
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 110
Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis 110
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 109
BRAF is a therapeutic target in aggressive thyroid carcinoma. 108
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice 108
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage 107
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 107
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 107
Different mutations of the RET gene cause different human tumoral diseases. 105
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. 103
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. 102
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation 102
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 101
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 100
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism 100
Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities 99
Iron and ferritin modulate MHC Class i expression and NK cell recognition 98
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. 97
RET\PTC activation in human thyroid carcinomas 95
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. 95
POR Campania FESR SATIN 95
Benzimidazole Analogues and related methods 93
Activation of RET oncogene and thyroid carcinogenesis 92
Molecular mechanisms of RET activation in human cancer. 91
Attacking cancer with molecularly targeted agents 91
Molecular mechanisms of RET activation in human neoplasia 89
Ret-mediated mitogenesis requires Src kinase activity. 88
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 87
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B 87
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. 87
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation 87
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 86
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 86
Molecular mechanisms of RET activation in human neoplasia. 86
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affaected by familial medullary thyroid carcinoma. 85
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 84
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. 83
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 82
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. 81
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. 79
Oncogenic rearrangements driving ionizing radiation-associated human cancer 79
Ret-mediated mitogenesis requires Src kinase activity 78
Molecular targeting of the RET kinase in thyroid cancer 78
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. 77
Receptor tyrosine kinases as targets for anticancer therapeutics 76
Central role of RET in thyroid cancer 75
POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE 74
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application 73
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. 72
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A 72
Receptor tyrosine kinase inhibitors in thyroid cancer. 71
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 71
Minireview:RET:normal and abnormal functions 68
Ret-mediated mitogenesis requires Src kinase activity. 68
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma 67
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. 67
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors 66
Molecular Mechanism of RET in Human Cancer 66
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells 66
Totale 11.006
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.402
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022588 0 0 17 3 5 20 25 31 103 36 119 229
2022/2023643 123 49 5 52 76 65 10 54 92 60 42 15
2023/2024568 22 93 62 48 44 53 22 54 16 8 110 36
2024/20252.917 162 218 25 25 58 144 355 198 215 307 910 300
2025/20265.696 714 369 536 529 907 220 686 292 730 390 159 164
2026/2027453 113 181 159 0 0 0 0 0 0 0 0 0
Totale 12.160